Study guide
1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS)
Certified Addictions Registered Nurse - Advanced Practice CARN-AP
Track your progress as you read
Finished sections get a check mark.
1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice
About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care
2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance
1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene
3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone
2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)
4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal
3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications
5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)
4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen
6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders
5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds
7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions
6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management
8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions
7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice
9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning
8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy
10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines
9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)
11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications
10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP
12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing
11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation
13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy
12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine
14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction
13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education
15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition
14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol
16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder
15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support
17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations
16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders
18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy
17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education
19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse
18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM
20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)
19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching
21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)
20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation
22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)
21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction
1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS)
Key Takeaways Explain This Topic AI
DSM-5-TR establishes 11 diagnostic criteria across four domains within a 12-month window; severity is stratified as mild (2-3), moderate (4-5), and severe (6+).
The critical diagnostic exception mandates that tolerance and withdrawal do NOT count toward OUD when opioids are taken solely under appropriate medical supervision.
Remission specifiers require sustained cessation of all criteria except craving: early remission (3 to 12 months) and sustained remission (≥12 months), with specifiers for maintenance therapy and controlled environments.
The Clinical Opiate Withdrawal Scale (COWS) scores 11 signs (5-12 mild, 13-24 moderate, 25-36 moderately severe, >36 severe); buprenorphine induction requires objective autonomic verification, never subjective reports alone.
Chronic synthetic fentanyl exposure causes prolonged lipophilic tissue sequestration and delayed withdrawal emergence (up to 24-72 hours), substantially elevating precipitated withdrawal risk.
Last updated: September 2026
Diagnostic Frameworks, DSM-5-TR Criteria & Clinical Opiate Withdrawal Scale (COWS)
Opioid Use Disorder (OUD) is a chronic, relapsing neurobiological disease characterized by neurochemical adaptations in reward, motivational, and autonomic brain circuits. For the Advanced Practice Registered Nurse (APRN) specializing in addictions (CARN-AP), expert diagnosis requires rigorous application of DSM-5-TR criteria, differentiation between normal physiological tolerance and compulsive pathology, mastery of objective withdrawal staging, and an understanding of the erratic pharmacokinetics introduced by synthetic lipophilic contaminants such as illicitly manufactured fentanyl.
DSM-5-TR Diagnostic Criteria for Opioid Use Disorder
The American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) conceptualizes OUD as a problematic pattern of opioid use leading to clinically significant impairment or distress. Diagnosis requires meeting at least 2 of 11 criteria within a 12-month period .
The 11 criteria span four functional domains:
1. Impaired Control
Criterion 1 (Larger amounts/duration): Opioids are often taken in larger amounts or over a longer period than was intended.
Criterion 2 (Unsuccessful cut-down): Persistent desire or unsuccessful efforts to cut down or control opioid use.
Criterion 3 (Excessive time spent): A great deal of time is spent in activities necessary to obtain the opioid, use the opioid, or recover from its effects.
Criterion 4 (Craving): Craving, or a strong desire or urge to use opioids.
2. Social Impairment
Criterion 5 (Role failure): Recurrent opioid use resulting in a failure to fulfill major role obligations at work, school, or home.
Criterion 6 (Interpersonal problems): Continued opioid use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of opioids.
Criterion 7 (Activities abandoned): Important social, occupational, or recreational activities are given up or reduced because of opioid use.
3. Risky Use
Criterion 8 (Hazardous use): Recurrent opioid use in situations in which it is physically hazardous (e.g., driving while intoxicated, injecting in unsanitary settings).
Criterion 9 (Physical/psychological harm): Continued opioid use despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance.
4. Pharmacological Criteria
Criterion 10 (Tolerance): A need for markedly increased amounts of opioids to achieve intoxication or desired effect, or a markedly diminished effect with continued use of the same amount of an opioid.
Criterion 11 (Withdrawal): The characteristic opioid withdrawal syndrome, or opioids (or a closely related substance) are taken to relieve or avoid withdrawal symptoms. +---------------------------------------------------------------------------------------+
- | DSM-5-TR OUD SEVERITY |
- +-----------------------------------+---------------------------------------------------+
- | Severity Subtype | Diagnostic Criteria Count (within 12-month span) |
- +-----------------------------------+---------------------------------------------------+
- | Mild | 2 to 3 criteria met |
- | Moderate | 4 to 5 criteria met |
- | Severe | 6 or more criteria met |
- +-----------------------------------+---------------------------------------------------+
- The Mandatory Medical Supervision Exception
Critical Clinical Rule: Under DSM-5-TR, Criterion 10 (Tolerance) and Criterion 11 (Withdrawal) are NOT counted toward a diagnosis of Opioid Use Disorder when the patient is taking opioids solely under appropriate medical supervision .
Physiological neuroadaptation (receptor desensitization, beta-arrestin signaling down-regulation, and cellular dependence) is an expected, inevitable biological response to chronic opioid administration. A patient with cancer or chronic non-cancer pain taking extended-release morphine exactly as prescribed by their clinician will exhibit both tolerance and acute withdrawal upon abrupt cessation. However, in the absence of behavioral signs from the Impaired Control, Social Impairment, or Risky Use domains, this patient has zero qualifying criteria and does not have an Opioid Use Disorder.
Remission Specifiers and Course Criteria
When tracking treatment outcomes and diagnostic evolution, APRNs apply precise DSM-5-TR remission specifiers:
Early Remission: Full criteria for OUD have previously been met, but no criteria have been met for at least 3 months and less than 12 months (with the sole exception that Criterion 4, Craving , may still be present).
Sustained Remission: Full criteria for OUD have previously been met, but no criteria have been met for 12 months or longer (again, with the sole exception of Craving ).
"On Maintenance Therapy": Applied if the individual is currently taking a prescribed agonist (methadone), partial agonist (buprenorphine), or antagonist (naltrexone) medication and meets no criteria other than tolerance/withdrawal to that prescribed medication.
"In a Controlled Environment": Applied if the individual is in an environment where access to opioids is restricted (e.g., closely supervised residential treatment center, locked psychiatric hospital, correctional facility).
Opioid Intoxication vs. Opioid Withdrawal Toxidromes
Accurate physical assessment requires recognizing the polar neurobiological presentations of opioid intoxication versus withdrawal. Opioids act on central mu-opioid receptors (MOR) linked to inhibitory G-proteins ( G i / o G_{i/o} G i / o ), which suppress adenylyl cyclase, decrease cyclic AMP (cAMP), open inwardly rectifying potassium channels, and close voltage-gated calcium channels. This inhibits neuronal firing in the locus coeruleus —the primary noradrenergic center in the pons.
During chronic opioid use, homeostatic up-regulation of adenylyl cyclase occurs. When opioids are withheld, displaced, or cleared, the uninhibited locus coeruleus fires catastrophically, producing a massive noradrenergic storm that drives acute withdrawal symptoms.
Assessment Parameter Opioid Intoxication Opioid Withdrawal
Pupils Miosis (pinpoint, <2 mm), sluggish to light (Note: severe hypoxia may cause terminal mydriasis) Mydriasis (dilated, >4-5 mm), photophobia
Vital Signs Bradypnea (<8-10 breaths/min), bradycardia, hypotension, hypothermia Tachycardia (>80-100 bpm), hypertension, tachypnea, mild hyperthermia
Mental Status Sedation, somnolence, euphoria shifting to apathy, coma Severe anxiety, restlessness, irritability, dysphoria, drug craving
Skin & Secretions Warm, flushed, dry skin Piloerection ("gooseflesh"), profuse diaphoresis , rhinorrhea , lacrimation
Gastrointestinal Decreased bowel sounds , constipation, delayed gastric emptying Hyperactive bowel sounds , severe abdominal cramping, nausea, projectile vomiting, watery diarrhea
Neuromuscular Slurred speech, hyporeflexia, flaccidity Coarse tremors, muscle twitching, myalgias, arthralgias, excessive yawning
Clinical Opiate Withdrawal Scale (COWS)
The Clinical Opiate Withdrawal Scale (COWS) is an 11-item validated instrument administered by clinicians to quantify the severity of opioid withdrawal. Scoring guides clinical decision-making, symptom-triggered comfort pharmacotherapy, and buprenorphine induction timing. CLINICAL OPIATE WITHDRAWAL SCALE (COWS) SUMMARY
- 0 - 4: No / Minimal Withdrawal
- 5 - 12: Mild Withdrawal
- 13 - 24: Moderate Withdrawal <-- Standard target for safe buprenorphine induction (>=8-12)
- 25 - 36: Moderately Severe Withdrawal
- > 36: Severe Withdrawal
- The 11 COWS Assessment Items
Resting Heart Rate (measured for 1 full minute):
- 0 = pulse ≤ 80 \le 80 ≤ 80 bpm
- 1 = pulse 81-100 bpm
- 2 = pulse 101-120 bpm
- 4 = pulse > 120 > 120 > 120 bpm
Sweating (over past 1/2 hour not accounted for by room temperature):
- 0 = no report of chills or flushing
- 1 = subjective report of chills or flushing
- 2 = flushed or moist face
- 3 = beads of sweat on brow or face
- 4 = sweat streaming off face
Restlessness (observed during interview):
- 0 = able to sit still
- 1 = reports difficulty sitting still, but is able to do so
- 3 = frequent shifting or extraneous movements of legs/arms
- 5 = unable to sit still for more than a few seconds
Pupil Size:
- 0 = pupils pinned or normal size for room light
- 1 = pupils possibly larger than normal for room light
- 2 = pupils moderately dilated
- 5 = pupils so dilated that only the rim of the iris is visible
Bone or Joint Aches (if patient was having pain, only additional aches are scored):
- 0 = not present
- 1 = mild diffuse discomfort
- 2 = patient reports severe diffuse aching of joints/muscles
- 4 = patient is rubbing joints/muscles and is unable to sit still because of discomfort
Runny Nose or Tearing (not accounted for by cold symptoms or allergies):
- 0 = not present
- 1 = nasal stuffiness or unusually moist eyes
- 2 = nose running or tearing
- 4 = nose constantly running or tears streaming down cheeks
GI Upset (over last 1/2 hour):
- 0 = no GI symptoms
- 1 = stomach cramps
- 2 = nausea or loose stool
- 3 = vomiting or diarrhea
- 5 = multiple episodes of diarrhea or vomiting
Tremor (observation of outstretched hands):
- 0 = no tremor
- 1 = tremor can be felt, but not observed
- 2 = slight tremor observable
- 4 = gross tremor or muscle twitches
Yawning (observed during interview):
- 0 = no yawning
- 1 = 1 or 2 yawns during interview
- 2 = 3 or more yawns during interview
- 4 = yawning several times per minute
Anxiety or Irritability:
- 0 = none
- 1 = patient reports increasing irritability or anxiousness
- 2 = patient obviously irritable or anxious
- 4 = patient so irritable or anxious that participation in the interview is difficult
Gooseflesh Skin (piloerection):
- 0 = skin is smooth
- 3 = piloerection palpable or hairs standing up on arms
- 5 = prominent piloerection (cold turkey appearance)
- The "Objective vs. Subjective" Trap in Buprenorphine Induction
A critical pitfall on the CARN-AP exam is premature induction triggered by subjective patient complaints. Because buprenorphine has an exceptionally high receptor affinity ( K i ≈ 0.2 K_i \approx 0.2 K i ≈ 0.2 nM) but lower intrinsic activity (partial agonist), administering it while full agonists occupy mu receptors displaces those agonists and precipitates severe withdrawal.
Patients in early withdrawal frequently report severe subjective distress (10/10 cravings, anxiety, internal aches, mild nausea) when their actual autonomic signs are absent. If an APRN calculates a COWS score of 12 composed purely of subjective points (e.g., anxiety = 2, bone aches = 4, GI cramps = 1, restlessness report = 1, subjective chills = 1, subjective nausea = 2, score = 11), administering buprenorphine will precipitate acute withdrawal .
Core Practice Imperative: Induction requires objective autonomic signs verified on physical exam:
- Resting tachycardia (pulse >80-100 bpm)
- Visible pupil dilation (>4 mm in ambient light)
- Evident piloerection (gooseflesh)
- Observable resting tremor on outstretched hands
- Documented rhinorrhea or lacrimation
- Pharmacokinetics & Withdrawal Chronology Across Opioid Classes
The onset, peak, and duration of withdrawal depend on the elimination half-life and lipophilicity of the specific opioid. OPIOID WITHDRAWAL TIMELINES ACROSS CLASSES
- 1. Short-Acting Opioids (Heroin, IR Oxycodone, Morphine)
- Last Use |---- 6-12h ----|=========== 24-48h ===========|--------- 5-7 days ---------|
- Onset of signs Peak Severity Resolution
- 2. Long-Acting Opioids (Methadone)
- Last Use |---------- 36-72h ----------|======= Days 4-6 =======|------ 2-3 weeks ------|
- Onset of signs Peak Severity Resolution
- 3. Illicit Synthetic Fentanyl (Chronic / Lipophilic Exposure)
- Last Use |---------------- 24-72h ----------------|==== Erratic Clearance ====>|
- Unpredictable delayed emergence Prolonged tissue depot leaching
- Short-Acting vs. Long-Acting Opioids
Short-acting opioids (heroin, morphine, oxycodone): Withdrawal manifests within 6 to 12 hours post-use, peaks within 24 to 48 hours, and subsides over 5 to 7 days.
Long-acting opioids (methadone): Due to tissue accumulation and terminal half-life (24-36 hours), withdrawal emergence is delayed to 36 to 72 hours, peaks at 4 to 6 days, and persists for 2 to 3 weeks.
Fentanyl Lipophilicity and Adipose Sequestration Kinetics
Historically, fentanyl was classified as a short-acting synthetic opioid with an elimination half-life of 2 to 4 hours after single acute exposure. However, illicitly manufactured fentanyl (IMF) used chronically displays fundamentally altered pharmacokinetics:
Extreme Lipophilicity: Fentanyl is over 50 to 100 times more lipophilic than morphine, with a vast volume of distribution ( V d = 3 − 8 V_d = 3-8 V d = 3 − 8 L/kg).
Deep Tissue Sequestration: With repeated daily use, high concentrations saturate peripheral lipid stores and skeletal muscle.
Protracted Release: Following cessation, fentanyl leaches slowly and erratically from adipose depots back into the bloodstream, extending its terminal elimination half-life to 24 to 72 hours or longer .
The Precipitated Withdrawal Dilemma: Patients may test positive for urinary fentanyl metabolites for 2 to 3 weeks post-cessation. Patients frequently exhibit subjective dysphoria or early withdrawal while central mu receptors remain heavily occupied by depot-leached fentanyl. Standard buprenorphine induction at 12 to 24 hours in chronic fentanyl users carries a high risk of precipitated withdrawal, necessitating micro-induction protocols or delayed initiation based on rigorous objective COWS validation.